Xin Lang Cai Jing·2025-09-01 02:17Summary of Key Points Core Viewpoint - The financial performance of Haiprui Pharmaceutical Group shows a decline in revenue and net profit for the first half of 2025, indicating potential challenges in the company's operations and market conditions [2]. Group 1: Financial Performance - As of June 30, 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71% [2]. - The net profit attributable to shareholders for the same period was 422 million yuan, reflecting a significant year-on-year decline of 36.44% [2]. Group 2: Shareholder and Market Activity - As of August 29, 2023, Haiprui's stock price increased by 0.16%, with a trading volume of 74.417 million yuan [1]. - The company experienced a net financing outflow of 2.4477 million yuan on August 29, with a total financing and securities balance of 268 million yuan [1]. - The number of shareholders decreased by 7.29% to 26,300 as of June 30, 2025 [2]. Group 3: Dividend and Institutional Holdings - Haiprui has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the eighth largest shareholder, increasing its holdings by 6.3765 million shares to 11.3176 million shares [3].